• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Irwin Naturals Inc (OP: IWINF )

    0.5376 +0.2187 (+68.58%)
    Streaming Delayed Price Updated: 9:31 AM EDT, Jul 30, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 100
    Open 0.5376
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 0.3189
    Today's Range 0.5376 - 0.5376
    52wk Range 0.0500 - 1.080
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More
    Defense Dept. Funds Ketamine Study For PTSD Treatment  
    Via Benzinga
    Irwin Naturals' Bold Leap: Cannabis, Psychedelics Drive Q3 Buzz Despite Falling Revenue & Surging Losses
    Irwin Naturals Inc. 
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis

    Performance

    YTD
    +139.15%
    +139.15%
    1 Month
    +68.63%
    +68.63%
    3 Month
    +975.20%
    +975.20%
    6 Month
    +287.04%
    +287.04%
    1 Year
    -50.22%
    -50.22%

    More News

    Read More
    Psyched: Three Noteworthy Psychedelics M&As, Colorado's Regulations, Exclusive Financing & More
    Via Benzinga
    Irwin Naturals Revenue Sluggish In Q2, Net Loss Grows YOY
    Via Benzinga
    Irwin Naturals Launches Trio Of Cannabis Tinctures In California
    Via Benzinga
    Cannabis Stock Gainers And Losers From August 25, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Irwin Naturals Q1 FY23 Revenue Stagnates YoY, What About Adjusted EBITDA?
    Via Benzinga
    Psyched: LSD Microdosing For Depression, DMT For Anxiety, MDMA Octopuses And More
    Via Benzinga
    Bullish Thursday For Marijuana Stocks - EVIO, Tetra Bio Pharma Among Top Gainers
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Irwin Naturals FY22 Revenue Declines 10.8%, What About Adjusted EBITDA?
    Via Benzinga
    Psyched: Psychedelics Reimbursement, Amanita Muscaria Boom, $53M Material Breach Lawsuit & More
    Via Benzinga
    Marijuana Stock Movers For August 15, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Cannabis Scandal And Resignation Of Oregon Official, USCC's New Leadership & More Executive Moves
    Via Benzinga
    Cannabis Stock Movers For August 10, 2023
    Via Benzinga
    Topics Cannabis
    Exposures Cannabis
    Psychedelics Company Confirms Shares Spinout, Another Fails To File Financials & Gets CTO Issue
    Via Benzinga
    Cantor Fitzgerald Discontinues Research Coverage Of The Cannabis Sector
    Via Benzinga
    Cannabis Stock Movers For July 27, 2023
    Via Benzinga
    Psyched: Australia As Psychedelics Hub, Advanced Scans Of Brain On DMT, New PAC For Congressional Influence, 9 States Advancing Bills & More
    Via Benzinga
    Irwin Naturals Cannabis Products Launch Nationwide In Canada
    Via Benzinga
    Irwin Naturals Acquires Ketamine Media
    Via Benzinga
    Psyched: 22 States With Reform Bills, Ketamine Therapy Services Today, Oscars On Shrooms & More
    Via Benzinga
    Major Ketamine Clinics Chain Decides Not To Pursue Acquisition Deal
    Via Benzinga
    In-Clinic Ketamine Businesses Are Shutting Down All Across The US, A Rising Trend?
    Via Benzinga
    Here Are The Year's Highest Priced Psychedelics Stocks In US Markets
    Via Benzinga
    Braxia Scientific's Q3 2023 Finances, Update On Upcoming Acquisition With Irwin Naturals
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.